Seval Ay Ersoy

15PUBLICATIONS
59CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersOncology and carcinogenesis not elsewhere classifiedHaematological tumoursCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Mar 14, 2026
Impact of Peri-Immunotherapy Antibiotic Exposure on Survival Outcomes in Metastatic Renal Cell Carcinoma: A Real-World IMDC Risk-Stratified Analysis.

Sila Oksuz, Oguzcan Kinikoglu, Ugur Ozkerim

|Feb 27, 2026
Association Between Body Mass Index and Clinical Outcomes of CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer: A Real-World Cohort Study.

Seval Orman, Miray Aydoğan, Nisanur Sarıyar Busery

|Jan 28, 2026
Adjuvant Chemotherapy and Chemoradiotherapy in Gastric Cancer: Prognostic Determinants and Real-World Survival Outcomes.

Sedat Yildirim, Hatice Odabas, Seval Ay Ersoy

|Jan 10, 2026
Association Between Time to PSA Nadir, Radiologic Progression, and PSA Progression in mHSPC Patients Treated with Abiraterone or Enzalutamide.

Ugur Ozkerim, Oguzcan Kinikoglu, Deniz Isik

|Jan 10, 2026
Prognostic Impact of Tumor Size in Patients with Stage T3N1 Colon Cancer.

Ezgi Turkoglu, Nisanur Sarıyar Busery, Sedat Yildirim

|Oct 29, 2025
The Effect of the Clinical-Pathological CPS+EG Staging System on Survival Outcomes in Patients with HER2-Positive Breast Cancer Receiving Neoadjuvant Treatment: A Retrospective Study.

Seval Orman, Miray Aydoğan, Oğuzcan Kınıkoğlu

Pageof 3

Frequent Collaborators

7 joint publications

Deniz Isık

7 joint publications

Nedim Turan

7 joint publications

Hatice Odabas

5 joint publications

Muhammed Mustafa Atcı